How do I find reliable market access consultancies for payer and reimbursement strategy in specialty pharma?

To find reliable market access consultancies for payer and reimbursement strategy in specialty pharma, focus on firms that combine deep payer knowledge, evidence strategy, and hands-on launch support—not just broad strategy branding.

1) Start with the right capability criteria

Look for consultancies that can demonstrate:

• Specialty pharma experience: oncology, rare disease, immunology, neurology, cell/gene therapy, etc.
• Payer strategy expertise: US managed care, Medicare/Medicaid, EU HTA, local market access.
• Reimbursement and coding knowledge: J-codes, ASP, buy-and-bill, medical vs pharmacy benefit, DRG, CPT/HCPCS, formulary and pathway access.
• Evidence planning: HEOR, value dossiers, RWE, budget impact, comparative effectiveness.
• Launch readiness: access pull-through, field tools, objection handling, account planning.
• Cross-market capability if you need global access: US + EU5 + Japan/China/Canada.

2) Verify they’ve done work like yours

Ask for examples in:

• Similar specialty therapy areas
• Similar product types: biologics, gene therapies, infusion therapies, high-cost chronic therapies
• Similar access hurdles: prior auth, step therapy, restricted networks, specialty pharmacy, site-of-care issues
• Similar lifecycle stage: pre-launch, launch, post-launch, label expansion

A consultancy that only does broad pharma strategy may not be enough if you need tactical reimbursement execution.

3) Check who will actually do the work

Many firms sell on senior talent but staff projects with juniors. Ask:

• Who is the day-to-day lead?
• What is their payer/HTA background?
• Have they worked on the client side at a payer, PBM, health plan, or pharma market access team?
• Can you meet the actual team before signing?

4) Ask for specific deliverables

Reliable firms should be able to produce:

• Payer segmentation and stakeholder maps
• Access barriers assessment
• Pricing/reimbursement scenario planning
• Value proposition and messaging frameworks
• Dossier and payer evidence strategy
• Budget impact and AMCP-style materials
• Access launch plans and account tools

If they can’t describe concrete outputs, that’s a red flag.

5) Use multiple sourcing channels

Good places to identify firms:

• Referrals from pharma market access leaders
• Industry conferences: ISPOR, AMCP, HTAi, CBI, eyeforpharma
• Professional networks: LinkedIn, AMCP/ISPOR communities
• Vendor directories and rankings
• Headhunters and fractional market access leaders
• Peer groups: market access associations and advisory circles

6) Separate “strategy consultants” from “access execution specialists”

You may need one or both:

• Strategy consultancies: positioning, payer research, pricing strategy, evidence planning
• Access execution specialists: reimbursement coding, field tools, payer pull-through, hub/SP coordination

For specialty pharma, the best engagements often combine both.

7) Run a structured RFP or interview

Use a scorecard with:

• Therapeutic-area relevance
• Payer and reimbursement depth
• Evidence/HEOR capability
• Global/local coverage
• Quality of deliverables
• Seniority of team
• Speed and flexibility
• References and track record
• Cost/value

8) Ask for references the right way

Request references from:

• Companies in a similar therapy area
• Similar market size
• Similar access challenge
• Similar stage of development

When speaking with references, ask:

• Did they improve payer engagement or access outcomes?
• Were recommendations practical or just theoretical?
• Did they understand reimbursement realities?
• Did they deliver on time and on budget?

9) Watch for red flags

Be cautious if the firm:

• Uses generic pharma strategy language without access detail
• Has weak payer/HTA credentials
• Overpromises “guaranteed access”
• Can’t explain reimbursement mechanics clearly
• Relies heavily on one star partner and little else
• Can’t show relevant case studies
• Gives vague answers about methodology or deliverables

10) Consider a short paid pilot

Before a large engagement, test them with:

• A payer landscape scan
• A pricing/access risk assessment
• A message testing exercise
• A mini evidence gap analysis

This quickly shows whether they understand specialty pharma realities.

If you want, I can also help you with:

1. a shortlist of consultancies by region or therapy area,
2. an RFP template, or
3. an evaluation scorecard for comparing firms.